Munin: Hjem (original) (raw)

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial

Viermyr, Hans-Kittil; Tonby, Kristian; Ponzi, Erica; Trouillet-Assant, Sophie; Poissy, Julien; Arribas, José R.; Dyon-Tafani, Virginie; Bouscambert-Duchamp, Maude; Assoumou, Lambert; Halvorsen, Bente; Tekin, Nuriye Basdag; Diallo, Alpha; de Gastines, Lucie; Munthe, Ludvig A; Murphy, Sarah Louise Mikalsen; Ueland, Thor; Michelsen, Annika Elisabet; Lund-Johansen, Fridtjof; Aukrust, Pål; Mootien, Joy; Dervieux, Benjamin; Zerbib, Yoann; Richard, Jean-Christophe; Prével, Renaud; Malvy, Denis; Timsit, Jean-François; Peiffer-Smadja, Nathan; Roux, Damien; Piroth, Lionel; Ait-Oufella, Hafid; Vieira, Cesar; Dalgard, Olav; Heggelund, Lars; Müller, Karl Erik; Møller, Jannicke Horjen; Kildal, Anders Benjamin; Skogen, Vegard; Aballi, Saad; Øgaard, Jonas Daniel Sjøberg; Dyrhol-Riise, Anne Margarita; Tveita, Anders; Alirezaylavasani, Amin; Costagliola, Dominique; Yazdanpanah, Yazdan; Olsen, Inge Christoffer; Dahl, Tuva Børresdatter; Kared, Hassen; Holten, Aleksander Rygh; Trøseid, Marius (Journal article; Tidsskriftartikkel; Peer reviewed, 2024-12-27)

Background - The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe ...